AC-262,536

Description

Product Description:

This product is presented in a 50 mL liquid form with a concentration of 25 mg/mL, resulting in a total of 50 x 25 mg of the active ingredient.

Chemical Properties:

• Molecular Weight (M.Wt): 389.33 g/mol
• Chemical Formula: C₁₉H₁₄F₃N₃O₃
• CAS Number: 841205-47-8

Composition:

The formulation is comprised of the following key elements:

• Carbon (C): 19 atoms
• Hydrogen (H): 14 atoms
• Fluorine (F): 3 atoms
• Nitrogen (N): 3 atoms
• Oxygen (O): 3 atoms

Solubility:

This compound shows solubility in polyglycols, making it suitable for use in various formulations that utilize these solvents.

Purity:

The product boasts a high purity level of >99%, ensuring minimal presence of impurities and optimal effectiveness.

Storage Conditions:

For maintaining the integrity and stability of the compound, it should be stored at 20℃. Under these conditions, the product is expected to retain its efficacy for a period of 2 years.

Pharmacokinetics:

• Half-Life: The elimination half-life of this compound is approximately 24 hours, indicating that it may require once-daily dosing in therapeutic applications.

This detailed overview encapsulates the essential properties and handling recommendations for the product, ensuring informed usage and storage.

Le informazioni fornite corrispondono a Ostarine, o MK-2866, un modulatore selettivo dei recettori degli androgeni (SARM). Qui ci sono alcune referenze scientifiche che supportano le informazioni sugli ingredienti:

1. Basaria, S., Collins, L., Dillon, E.L. et al. (2013). “The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.” Journals of Gerontology. Retrieved from https://academic.oup.com/biomedgerontology/article/68/1/87/570520
2. Dalton, James T, et al. (2011). “The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial.” The Journal of Cachexia, Sarcopenia and Muscle. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1007/s13539-011-0034-6
3. Zhang, X., Sui, Z. (2013). “Deciphering the selective androgen receptor modulators paradigm.” Expert Opinion on Drug Discovery. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23231475
4. National Center for Biotechnology Information. “PubChem Compound Summary for CID 11326715, (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide.” PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/11326715
5. AllChemicals.info. “Chemical Database: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide.” Retrieved from https://www.allchemicals.info/Chemical_Database/2S-3-4-cyanophenoxy-N-4-cyano-3-trifluoromethylphenyl-2-hydro